Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christy Chuang-Stein

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Pharmaceutical Statistics|November 28, 2006
Sample size and the probability of a successful trialChristy Chuang-Stein
Biometrical Journal. Biometrische Zeitschrift|January 24, 2007
A cautionary note on design implications when the primary analysis is a stratified analysis of a binary endpointChristy Chuang-Stein
Pharmaceutical Statistics|January 15, 2010
Reporting cumulative proportion of subjects with an adverse event based on data from multiple studiesChristy Chuang-Stein, Mohan Beltangady
Pharmaceutical Statistics|May 25, 2013
Strong control over multiple endpoints: are we adding value to the assessment of medicines?Andrew Stone, Christy Chuang-Stein
Pharmaceutical Statistics|September 29, 2016
A comparison of five approaches to decision-making for a first clinical trial of efficacySimon Kirby, Christy Chuang-Stein
Pharmaceutical Statistics|July 22, 2008
What should be the role of homogeneity testing in adaptive trials?Paul Gallo, Christy Chuang-Stein
Pharmaceutical Statistics|July 12, 2022
The Acute Stroke Therapy by Inhibition of Neutrophils study - Key features and impactSimon Kirby, Christy Chuang-Stein
Biometrical Journal. Biometrische Zeitschrift|September 3, 2015
Implementation of AMNOG: An industry perspectiveFriedhelm Leverkus, Christy Chuang-Stein
Journal of Biopharmaceutical Statistics|November 9, 2010
FDA draft guidance on adaptive design clinical trials: Pfizer's perspectiveChristy Chuang-Stein, Mohan Beltangady
Pharmaceutical Statistics|September 4, 2014
The shrinking or disappearing observed treatment effectChristy Chuang-Stein, Simon Kirby
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Pharmaceutical Statistics|November 28, 2006
Sample size and the probability of a successful trialChristy Chuang-Stein
Biometrical Journal. Biometrische Zeitschrift|January 24, 2007
A cautionary note on design implications when the primary analysis is a stratified analysis of a binary endpointChristy Chuang-Stein
Pharmaceutical Statistics|January 15, 2010
Reporting cumulative proportion of subjects with an adverse event based on data from multiple studiesChristy Chuang-Stein, Mohan Beltangady
Pharmaceutical Statistics|May 25, 2013
Strong control over multiple endpoints: are we adding value to the assessment of medicines?Andrew Stone, Christy Chuang-Stein
Pharmaceutical Statistics|September 29, 2016
A comparison of five approaches to decision-making for a first clinical trial of efficacySimon Kirby, Christy Chuang-Stein
Pharmaceutical Statistics|July 22, 2008
What should be the role of homogeneity testing in adaptive trials?Paul Gallo, Christy Chuang-Stein
Pharmaceutical Statistics|July 12, 2022
The Acute Stroke Therapy by Inhibition of Neutrophils study - Key features and impactSimon Kirby, Christy Chuang-Stein
Biometrical Journal. Biometrische Zeitschrift|September 3, 2015
Implementation of AMNOG: An industry perspectiveFriedhelm Leverkus, Christy Chuang-Stein
Journal of Biopharmaceutical Statistics|November 9, 2010
FDA draft guidance on adaptive design clinical trials: Pfizer's perspectiveChristy Chuang-Stein, Mohan Beltangady
Pharmaceutical Statistics|September 4, 2014
The shrinking or disappearing observed treatment effectChristy Chuang-Stein, Simon Kirby
Pageof 4